Tuesday, July 17, 2012 11:11:06 PM
So what is your answer?
The first three seem like the most popular guesses, we have an I don't care too. Weird answer there!
You never answered - Which will be the first product announced for the BE trials and 5052b studies?
Oxycodone
Hydromorphone
Morphine
Percodin
Percocet
Oxymorphone
?????
So many possibilities
Funding to be announced soon too..
so we have (besides the current 4 commercial products)
5 products pending FDA approval
4 products in scaleup
Return of Lodrane
HITKs generic of a 100m branded product
MIK001 with Actavis/Mikah
HK deal
Completion of second mfg facility - currently requires FDA approval
Plus Additional products etc....
CEO - "My vision is to create a line of abuse resistant opioid products using our patented technology. Push comes to shove, that's where the value -- the true large value of the Company is, is in the creation of that line of abuse resistant products. Nobody in management is working to see this Company grow by million-dollar increments.
We are going for the doubles, the triples, and the home runs. And we think we can do that.
If you look at the abuse resistant market and you look at some of the problems that other companies have had in manufacturing their products on a consistent basis, we think one of the big advantages that we have is that we have a system that can be consistently manufactured over and over again with many different products."
The first three seem like the most popular guesses, we have an I don't care too. Weird answer there!
You never answered - Which will be the first product announced for the BE trials and 5052b studies?
Oxycodone
Hydromorphone
Morphine
Percodin
Percocet
Oxymorphone
?????
So many possibilities
Funding to be announced soon too..
so we have (besides the current 4 commercial products)
5 products pending FDA approval
4 products in scaleup
Return of Lodrane
HITKs generic of a 100m branded product
MIK001 with Actavis/Mikah
HK deal
Completion of second mfg facility - currently requires FDA approval
Plus Additional products etc....
CEO - "My vision is to create a line of abuse resistant opioid products using our patented technology. Push comes to shove, that's where the value -- the true large value of the Company is, is in the creation of that line of abuse resistant products. Nobody in management is working to see this Company grow by million-dollar increments.
We are going for the doubles, the triples, and the home runs. And we think we can do that.
If you look at the abuse resistant market and you look at some of the problems that other companies have had in manufacturing their products on a consistent basis, we think one of the big advantages that we have is that we have a system that can be consistently manufactured over and over again with many different products."
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
